FDA Brief

Company record

J&J INNOVATIVE MEDICINE

0 FDA warning letters since 2023 and 1 recall in the last 12 months.

Get an email the day FDA posts anything new about J&J INNOVATIVE MEDICINE.

Recalls

ReportedClassFirmProduct and reason
Oct 14 Class II J&J INNOVATIVE MEDICINE
Drug
IMAAVY (nipocalimab-aahu) Injection, 300 mg /1.62 mL (185 mg/mL) per single-dose vial, For Intravenous Infusion After Dilution, Rx only, Manufactured by: Janssen Biotech, Inc., Horsham, PA 19044. NDC: 57894-800-01
Presence of particulate matter.